DZ2376A1 - Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. - Google Patents
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.Info
- Publication number
- DZ2376A1 DZ2376A1 DZ970226A DZ970226A DZ2376A1 DZ 2376 A1 DZ2376 A1 DZ 2376A1 DZ 970226 A DZ970226 A DZ 970226A DZ 970226 A DZ970226 A DZ 970226A DZ 2376 A1 DZ2376 A1 DZ 2376A1
- Authority
- DZ
- Algeria
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- sulfonamide derivatives
- derivatives process
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9626377.7A GB9626377D0 (en) | 1996-12-19 | 1996-12-19 | Novel compounds |
| GBGB9700901.3A GB9700901D0 (en) | 1997-01-17 | 1997-01-17 | Novel compounds |
| GBGB9722757.3A GB9722757D0 (en) | 1997-10-27 | 1997-10-27 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DZ2376A1 true DZ2376A1 (fr) | 2002-12-28 |
Family
ID=27268644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DZ970226A DZ2376A1 (fr) | 1996-12-19 | 1997-12-07 | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6423717B1 (fr) |
| EP (1) | EP0946539B1 (fr) |
| JP (1) | JP2001506646A (fr) |
| KR (1) | KR20000069554A (fr) |
| CN (1) | CN1246116A (fr) |
| AP (1) | AP1277A (fr) |
| AR (1) | AR010795A1 (fr) |
| AT (1) | ATE247099T1 (fr) |
| AU (1) | AU729056B2 (fr) |
| BG (1) | BG103530A (fr) |
| BR (1) | BR9713734A (fr) |
| CA (1) | CA2275492A1 (fr) |
| CZ (1) | CZ220399A3 (fr) |
| DE (1) | DE69724142T2 (fr) |
| DZ (1) | DZ2376A1 (fr) |
| EA (1) | EA002351B1 (fr) |
| ES (1) | ES2203831T3 (fr) |
| HU (1) | HUP0000658A3 (fr) |
| ID (1) | ID22821A (fr) |
| IL (1) | IL130297A0 (fr) |
| MA (1) | MA24426A1 (fr) |
| NO (1) | NO993003D0 (fr) |
| NZ (1) | NZ335970A (fr) |
| OA (1) | OA11066A (fr) |
| PE (1) | PE46899A1 (fr) |
| PL (1) | PL334337A1 (fr) |
| SK (1) | SK80899A3 (fr) |
| TR (1) | TR199901361T2 (fr) |
| TW (1) | TW418205B (fr) |
| UY (1) | UY24819A1 (fr) |
| WO (1) | WO1998027081A1 (fr) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| JP2002511097A (ja) | 1997-07-11 | 2002-04-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 |
| EP1053227B1 (fr) | 1998-01-29 | 2008-11-05 | Amgen Inc. | MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR$g(g)) |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| JP2003518057A (ja) * | 1999-12-21 | 2003-06-03 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ｉｉ受容体アンタゴニスト |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
| SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| US6818639B2 (en) | 2000-07-21 | 2004-11-16 | Biovitrum Ab | Pharmaceutical combination formulation and method of treatment with the combination |
| ATE478857T1 (de) * | 2000-09-18 | 2010-09-15 | Toa Eiyo Ltd | N-substituierte benzothiophensulfonamid-derivate |
| US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| AU2002215047A1 (en) | 2000-11-21 | 2002-06-03 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
| EP1344525A4 (fr) | 2000-12-22 | 2005-05-25 | Ishihara Sangyo Kaisha | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
| WO2002088101A2 (fr) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de bace |
| US6743796B2 (en) | 2001-05-07 | 2004-06-01 | Wyeth | Piperazinyl-isatins |
| AR033879A1 (es) * | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
| AU2002256497A1 (en) * | 2001-05-07 | 2002-11-18 | Smithkline Beecham Corporation | Sulfonamides |
| JP2004529168A (ja) * | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| JP2004529164A (ja) * | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| EP1399137A4 (fr) * | 2001-05-07 | 2005-12-14 | Smithkline Beecham Corp | Sulfonamides |
| GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| RS88803A (sr) * | 2001-05-11 | 2007-02-05 | Biovitrum Ab., | Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns |
| NZ528450A (en) | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
| JP4187642B2 (ja) | 2001-06-07 | 2008-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体親和性を有する新規インドール誘導体 |
| KR20090019894A (ko) | 2001-06-11 | 2009-02-25 | 바이오비트럼 에이비(피유비엘) | 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법 |
| ES2268113T3 (es) | 2001-06-15 | 2007-03-16 | F. Hoffmann-La Roche Ag | Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6. |
| US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| JP2005527463A (ja) * | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
| MXPA04001250A (es) * | 2001-08-10 | 2004-05-27 | Hoffmann La Roche | Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6). |
| EP1433479B8 (fr) * | 2001-09-05 | 2008-01-23 | Eisai R&D Management Co., Ltd. | Agents stimulant l'appetit et remedes contre l'anorexie |
| SE0103644D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
| EP1450806B1 (fr) * | 2001-11-09 | 2009-04-29 | Biovitrum AB (publ) | Utilisation de derives sulfonamide dans le traitement de l'obesite ou pour la reduction de prise d'aliments |
| RS44204A (sr) | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1 |
| RS44304A (sr) | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1 |
| ATE367160T1 (de) * | 2001-11-30 | 2007-08-15 | Hoffmann La Roche | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma |
| CN1628109A (zh) * | 2002-02-05 | 2005-06-15 | 诺沃挪第克公司 | 新颖的芳基－与杂芳基－哌嗪 |
| US20070270432A1 (en) * | 2002-02-05 | 2007-11-22 | James Hagan | Novel Method |
| EP1495004A2 (fr) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Derives benzenesulfonamide et leurs usages comme dopamine d3 et d2 recepteur ligandes |
| US20050090485A1 (en) * | 2002-02-13 | 2005-04-28 | Bromidge Steven M. | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| US20050222124A1 (en) * | 2002-02-13 | 2005-10-06 | Bromidge Steven M | Benzenesulfonamide derivatives as antipsychotic agents |
| ES2386828T3 (es) | 2002-03-27 | 2012-08-31 | Glaxo Group Limited | Derivados de quinolina y su uso como ligandos 5-HT6 |
| US20040142948A1 (en) * | 2002-05-07 | 2004-07-22 | Dashyant Dhanak | Sulfonamides |
| KR100636475B1 (ko) * | 2002-05-13 | 2006-10-18 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 조절제로서 벤족사진 유도체 및 이의 용도 |
| NZ552282A (en) * | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| EP1897881A3 (fr) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central |
| WO2004035047A1 (fr) | 2002-10-18 | 2004-04-29 | F. Hoffmann-La Roche Ag | Indoles 4-piperazinyle benzenesulfonyle presentant une affinite pour le recepteur 5-ht6 |
| WO2004043369A2 (fr) * | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| WO2004043368A2 (fr) * | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| KR101078098B1 (ko) | 2003-01-14 | 2011-10-28 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료 |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| EP1597322A2 (fr) * | 2003-02-13 | 2005-11-23 | LANXESS Deutschland GmbH | Complexes metalliques servant de composes photoabsorbants dans la couche d'information de supports de donnees optiques |
| EP2415760A3 (fr) * | 2003-02-20 | 2012-02-22 | Encysive Pharmaceuticals, Inc. | Antagonistes du CCR-9 |
| TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
| US7262197B2 (en) * | 2003-03-31 | 2007-08-28 | Janssen Pharmaceutica, N.V | Phospholipase C inhibitors for use in treating inflammatory disorders |
| US6946466B2 (en) * | 2003-04-10 | 2005-09-20 | Schering Ag | Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
| US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
| US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| WO2005058858A1 (fr) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6 |
| RU2007107349A (ru) * | 2004-07-28 | 2008-09-10 | Глэксо Груп Лимитед (GB) | Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств |
| ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
| ATE520659T1 (de) | 2004-10-14 | 2011-09-15 | Abbott Gmbh & Co Kg | Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete azabicycloheptylverbindungen |
| CA2583983C (fr) * | 2004-10-14 | 2013-07-16 | Abbott Gmbh & Co. Kg | Composes heterocycliques convenant pour traiter des troubles sensibles a une modulation du recepteur d3 de la dopamine |
| WO2006062481A1 (fr) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central |
| EP1676841A1 (fr) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments |
| WO2006075808A1 (fr) * | 2005-01-12 | 2006-07-20 | Inje University | Composition pharmaceutique comprenant un inhibiteur de p25/cdk5 permettant de prevenir ou de traiter une maladie neurodegenerative |
| MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| EA013875B1 (ru) | 2005-08-12 | 2010-08-30 | Сувен Лайф Сайенсиз Лимитед | Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды |
| US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
| US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| PE20080176A1 (es) | 2006-03-31 | 2008-04-25 | Glaxo Group Ltd | Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) |
| MX2008013206A (es) | 2006-04-19 | 2008-10-22 | Abbott Gmbh & Co Kg | Compuestos heterociclicos adecuados para el tratamiento de trastornos que responden a modulacion del receptor de serotonina 5ht6. |
| CN101421234A (zh) * | 2006-04-19 | 2009-04-29 | 艾博特股份有限两合公司 | 适于治疗对5-羟色胺5ht6受体调节有反应的病症的杂环芳基砜 |
| CA2653062A1 (fr) | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | Nouveaux medicaments |
| KR20090040259A (ko) | 2006-05-29 | 2009-04-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도 |
| EP2086329B1 (fr) | 2006-10-26 | 2014-07-23 | The Arizona Board of Regents on behalf of the University of Arizona | Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides |
| ES2357584T3 (es) | 2007-01-08 | 2011-04-27 | Suven Life Sciences Limited | Compuestos de 5-(heterociclil) alquil-n-(arilsulfonil)indol y su uso como ligandos de 5-th6. |
| CN101578265B (zh) | 2007-01-10 | 2013-05-08 | 霍夫曼-拉罗奇有限公司 | 用作糜蛋白酶抑制剂的磺酰胺衍生物 |
| EP2155724A1 (fr) | 2007-03-23 | 2010-02-24 | Abbott GmbH & Co. KG | Composés azétidine appropriés pour traiter des troubles qui répondent à la modulation du récepteur 5-ht<sb>6</sb>de la sérotonine |
| EA016594B1 (ru) | 2007-05-03 | 2012-06-29 | Сувен Лайф Сайенсиз Лимитед | Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов |
| EP2014656A3 (fr) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Nouveaux antagonistes d'hétéocycliques h3 |
| DE602007012683D1 (de) * | 2007-07-19 | 2011-04-07 | Esteve Labor Dr | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
| CA2703157C (fr) | 2007-10-26 | 2013-02-05 | Suven Life Sciences Limited | Composes d'aminoarylsulfonamide et leur utilisation comme ligands de 5-ht6 |
| PA8802201A1 (es) * | 2007-11-02 | 2009-06-23 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2009128058A1 (fr) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Produits psycho-pharmaceutiques |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EA201001847A1 (ru) * | 2008-06-11 | 2011-08-30 | Айрм Ллк | Соединения и композиции, применяемые для лечения малярии |
| WO2010032258A1 (fr) * | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Composés amines d'arylsulfonamide et leur utilisation en tant que ligands de 5-ht<sb>6</sb> |
| US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| WO2010062321A1 (fr) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées |
| UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| KR101073703B1 (ko) | 2009-04-07 | 2011-10-14 | 한국화학연구원 | 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물 |
| US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| US8362010B2 (en) | 2009-04-30 | 2013-01-29 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| MX2011011519A (es) | 2009-04-30 | 2012-01-30 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. |
| CN102459197B (zh) | 2009-04-30 | 2015-08-19 | Abbvie公司 | 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物 |
| KR101463190B1 (ko) | 2010-01-05 | 2014-11-18 | 수벤 라이프 사이언시스 리미티드 | ５ｈｔ６ 수용체 리간드인 술폰 화합물 |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012059431A1 (fr) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine |
| WO2012059432A1 (fr) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 |
| ES2413911B1 (es) * | 2011-12-15 | 2014-05-14 | Universidad De Zaragoza | Agente inhibidor de la agregación del peptido beta amiloide. |
| NZ629855A (en) | 2012-03-20 | 2016-01-29 | Adamed Sp Zoo | Sulphonamide derivatives of benzylamine for the treatment of cns diseases |
| RU2693480C2 (ru) | 2013-03-14 | 2019-07-03 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| JP6267334B2 (ja) | 2013-07-25 | 2018-01-24 | ユニベルシテット ヤギェウォＵｎｉｗｅｒｓｙｔｅｔ Ｊａｇｉｅｌｌｏｎｓｋｉ | ５−ｈｔ６拮抗薬としてのピロロキノリン誘導体、それらの製造方法および使用 |
| US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
| CN105367472B (zh) * | 2014-08-12 | 2020-04-21 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
| CN105367473B (zh) * | 2014-08-12 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
| WO2019180176A1 (fr) | 2018-03-21 | 2019-09-26 | Spherium Biomed, S.L. | Composition pour le traitement de la schizophrénie et/ou de la psychose |
| US12156866B2 (en) | 2018-06-06 | 2024-12-03 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA3103995A1 (fr) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE81861C (fr) | ||||
| NZ193654A (en) * | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
| US4315014A (en) * | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
| EP0076072B1 (fr) * | 1981-09-24 | 1987-05-13 | BEECHAM - WUELFING GmbH & Co. KG | Sulfonamides |
| CN85106905A (zh) * | 1985-08-08 | 1987-02-04 | Fmc公司 | 含有1-芳基-δ2-1，2，4，-三唑啉-5-酮类的除草剂及其制备方法 |
| WO1990009787A1 (fr) * | 1989-02-27 | 1990-09-07 | The Du Pont Merck Pharmaceutical Company | Nouveaux sulfamides servant de radiosensibilisateurs |
| JPH04330057A (ja) * | 1991-05-01 | 1992-11-18 | Hiroyoshi Hidaka | アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩 |
| GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| DE4206531A1 (de) * | 1992-03-02 | 1993-09-09 | Bayer Ag | N-aryl-stickstoffheterocyclen |
| DE4303376A1 (de) * | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
| JP3328936B2 (ja) * | 1993-09-03 | 2002-09-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体 |
| EP0724580A1 (fr) * | 1993-10-19 | 1996-08-07 | Smithkline Beecham Plc | Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d |
| JPH09506101A (ja) * | 1993-12-07 | 1997-06-17 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ｄ拮抗薬として有用な複素環式ビフェニリルアミド類 |
| JPH10500960A (ja) * | 1994-05-28 | 1998-01-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ｄ−アンタゴニスト活性を有するアミド誘導体 |
| US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
-
1997
- 1997-12-07 DZ DZ970226A patent/DZ2376A1/fr active
- 1997-12-15 AU AU60904/98A patent/AU729056B2/en not_active Ceased
- 1997-12-15 BR BR9713734-0A patent/BR9713734A/pt not_active IP Right Cessation
- 1997-12-15 DE DE69724142T patent/DE69724142T2/de not_active Expired - Fee Related
- 1997-12-15 EP EP97954929A patent/EP0946539B1/fr not_active Expired - Lifetime
- 1997-12-15 SK SK808-99A patent/SK80899A3/sk unknown
- 1997-12-15 CA CA002275492A patent/CA2275492A1/fr not_active Abandoned
- 1997-12-15 CZ CZ992203A patent/CZ220399A3/cs unknown
- 1997-12-15 WO PCT/EP1997/007159 patent/WO1998027081A1/fr not_active Ceased
- 1997-12-15 NZ NZ335970A patent/NZ335970A/en unknown
- 1997-12-15 TR TR1999/01361T patent/TR199901361T2/xx unknown
- 1997-12-15 ES ES97954929T patent/ES2203831T3/es not_active Expired - Lifetime
- 1997-12-15 ID IDW990546A patent/ID22821A/id unknown
- 1997-12-15 AT AT97954929T patent/ATE247099T1/de not_active IP Right Cessation
- 1997-12-15 HU HU0000658A patent/HUP0000658A3/hu unknown
- 1997-12-15 KR KR1019997005497A patent/KR20000069554A/ko not_active Ceased
- 1997-12-15 PL PL97334337A patent/PL334337A1/xx unknown
- 1997-12-15 AP APAP/P/1999/001556A patent/AP1277A/en active
- 1997-12-15 IL IL13029797A patent/IL130297A0/xx unknown
- 1997-12-15 CN CN97181816A patent/CN1246116A/zh active Pending
- 1997-12-15 JP JP52734798A patent/JP2001506646A/ja not_active Ceased
- 1997-12-15 EA EA199900561A patent/EA002351B1/ru not_active IP Right Cessation
- 1997-12-17 MA MA24902A patent/MA24426A1/fr unknown
- 1997-12-17 PE PE1997001126A patent/PE46899A1/es not_active Application Discontinuation
- 1997-12-17 AR ARP970105951A patent/AR010795A1/es not_active Application Discontinuation
- 1997-12-18 TW TW086119136A patent/TW418205B/zh not_active IP Right Cessation
- 1997-12-18 UY UY24819A patent/UY24819A1/es not_active Application Discontinuation
-
1999
- 1999-06-18 NO NO993003A patent/NO993003D0/no not_active Application Discontinuation
- 1999-06-18 OA OA9900133A patent/OA11066A/en unknown
- 1999-06-25 BG BG103530A patent/BG103530A/bg unknown
-
2000
- 2000-08-21 US US09/643,200 patent/US6423717B1/en not_active Expired - Fee Related
-
2002
- 2002-05-29 US US10/157,258 patent/US6599904B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DZ2376A1 (fr) | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. | |
| DZ2457A1 (fr) | Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. | |
| DZ2197A1 (fr) | Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2407A1 (fr) | Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| DZ2300A1 (fr) | Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2299A1 (fr) | Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2634A1 (fr) | Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant. | |
| DZ2758A1 (fr) | Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ1957A1 (fr) | Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2621A1 (fr) | AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant. | |
| DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2666A1 (fr) | Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
| MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
| DZ2198A1 (fr) | Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant. | |
| MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2718136B1 (fr) | Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant. | |
| DZ3042A1 (fr) | Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2870A1 (fr) | Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant. | |
| DZ2227A1 (fr) | Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant. | |
| MA26686A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| MA26558A1 (fr) | Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. |